Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel
NASDAQ:FEED

Nanovibronix 4/15/2026 Earnings Report

Nanovibronix logo
$1.23 +0.09 (+7.89%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$1.20 -0.02 (-2.03%)
As of 05/5/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanovibronix EPS Results

Actual EPS
-$20.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanovibronix Revenue Results

Actual Revenue
$0.31 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanovibronix Announcement Details

Quarter
Date
4/15/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanovibronix Earnings Headlines

Nanovibronix (NASDAQ:FEED) Upgraded at Wall Street Zen
May 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30750683
ENvue Medical Announces 40th U.S. Hospital Customer with Addition of a Virginia Medical Center Affiliated with the Mayo Clinic Care Network
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3276995/0/en/envue-medical-announces-40th-u-s-hospital-customer-with-addition-of-a-virginia-medical-center-affiliated-with-the-mayo-clinic-care-network.html
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
 |  Brownstone Research (Ad)
ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39
March 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/24/3261198/0/en/envue-medical-expands-presence-within-a-major-michigan-health-system-and-grows-u-s-hospital-footprint-to-39.html
ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera
February 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/24/3243592/0/en/envue-medical-strengthens-patent-portfolio-with-new-uspto-notice-of-allowance-for-feeding-tube-combining-electromagnetic-navigation-with-direct-visualization-through-an-integrated-.html
Why is FEED stock soaring over 130% today?
January 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/why-is-feed-stock-soaring-over-130-today/ar-AA1VbOlf
See More Nanovibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanovibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanovibronix and other key companies, straight to your email.

About Nanovibronix

Nanovibronix (NASDAQ:FEED) (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies. Its offerings are intended to be user‑friendly, portable and suitable for repeated application, which supports adoption in ambulatory care and self‑care environments. Nanovibronix emphasizes clinical research and device development to validate therapeutic effects and to support regulatory and reimbursement discussions in the markets it serves.

As a publicly traded entity on the NASDAQ exchange under the ticker FEED, Nanovibronix engages in the full product lifecycle from research and development through manufacturing, regulatory engagement and distribution. The company has historically sought to expand market access through clinical collaborations, distribution partnerships and targeted commercialization initiatives. Detailed, current information about specific products, regulatory clearances, market geographies or executive leadership was not available in the material used to prepare this summary.

View Nanovibronix Profile
Earnings Tools